A comprehensive review on nanocarriers as a targeted delivery system for the treatment of breast cancer

Abstract

Breast cancer is the most common malignant tumour in women worldwide, as well as the leading cause of death from malignant tumours. All across the world, the incidence of breast cancer is steadily rising. Although numerous drugs acting through various mechanisms of action are available in the market as conventional formulations for the treatment of breast cancer, they face significant challenges in terms of bioavailability, dosing, and associated adverse effects, which severely limit their therapeutic efficacy. Several studies have shown that nanocarriers can significantly improve the drug’s bioavailability, reducing the need for frequent dosing and reducing the toxicity linked to high drug doses. The current review provides insight into the challenges associated with conventional breast cancer formulations and the need for oral nanoparticulate systems to overcome problems associated with conventional formulations. This review focuses on various topics, such as an in-depth analysis of potential anticancer drugs that have used nanocarrier technology to treat breast cancer successfully.

Keywords

Cancer / Breast cancer / Bioavailability / Signaling pathway / Nanocarrier

References

[1] Memariani Z, Abbas SQ, Ul Hassan SS, Ahmadi A, Chabra A. Naringin and naringenin as anticancer agents and adjuvants in cancer combination therapy: efficacy and molecular mechanisms of action, a comprehensive narrative review. Pharmacol Res. 2021;171:105264.

[2] Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104–1114.

[3] Adnan, M., Afzal, O., Altamimi, A.S., Alamri, M.A., Haider, T. and Haider, M.F., Development and optimization of Transethosomal gel of Apigenin for topical delivery: in-vitro, ex-vivo and cell line assessment. Int J Pharm, p.122506. 10.1016/j.ijpharm.2022.122506.

[4] Shahid A, Khan MM, Ahmad U, Haider MF, Ali A. Exploring liposomes for lung cancer therapy. Crit Rev Ther Drug Carrier Syst. 2022;39(4).

[5] Eggert JA, Palavanzadeh M, Blanton A. Screening and early detection of lung cancer. InSeminars in oncology nursing. 2017 May 1;33(2):129–140. WB Saunders.

[6] Henry NL, Shah PD, Haider I, Freer PE, Jagsi R, Sabel MS. Chapter 88: cancer of the breast. In: Niederhuber JE, Armitage JO, Doroshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 6th ed. Philadelphia, Pa: Elsevier;2020.

[7] Iacoviello L, Bonaccio M, de Gaetano G, Donati MB. Epidemiology of breast cancer, a paradigm of the “common soil” hypothesis. July Semin Cancer Biol. 2021;72:4–10. Academic Press.

[8] Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Nanocarriers as treatment modalities for hypertension. Drug Deliv. 2017;24(1):358–369.

[9] Sharma GN, Dave R, Sanadya J, Sharma P, Sharma K. Various types and management of breast cancer: an overview. \“J Adv Pharm Technol Research\”\“ (JAPTR)\”. 2010;1(2):109. https://www.japtr.org/text.asp?2010/1/2/109/72251.

[10] Chen Z, Yang J, Li S, et al. Invasive lobular carcinoma of the breast: a special histological type compared with invasive ductal carcinoma. PLoS One. 2017;12(9): e0182397.

[11] Martinez SR, Beal SH, Canter RJ, Chen SL, Khatri VP, Bold RJ. Medullary carcinoma of the breast: a population-based perspective. Med Oncol. 2011;28:738–744.

[12] Rakha EA, Lee AH, Evans AJ, et al. Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol. 2010;28(1):99–104.

[13] Stras S. Environmentally Responsive Liposomes for Treatment of Metastatic Triple Negative Breast Cancer. (Doctoral dissertation, Rutgers The State University of New Jersey, School of Graduate Studies);2018.

[14] Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. 10.1001/jama.2018.19323.

[15] Kamdje AHN, Etet PFS, Vecchio L, Muller JM, Krampera M, Lukong KE. Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. Cell Signal. 2014;26(12):2843–2856.

[16] Ahmad A. Pathways to breast cancer recurrence. Int Sch Res Notices. 2013. 2013.

[17] Ponde N, Bradbury I, Lambertini M, et al. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat. 2018;168:631–638.

[18] Mehta A, Tripathy D. Co-targeting estrogen receptor and HER2 pathways in breast cancer. Breast. 2014;23(1):2–9.

[19] Shaw HV, Koval A, Katanaev V. Targeting the Wnt signalling pathway in cancer: prospects and perils. Swiss Med Wkly. 2019;149:w20129. https://doi.org/10.4414/smw.2019.20129.

[20] Dhankhar R, Vyas SP, Jain AK, Arora S, Rath G, Goyal AK. Advances in novel drug delivery strategies for breast cancer therapy. Artificial Cells, Blood Substitutes. Biotechnology. 2010;38(5):230–249.

[21] Dranitsaris G, Yu B, Wang L, et al. Abraxane® versus Taxol® for patients with advanced breast cancer: a prospective time and motion analysis from a Chinese health care perspective. J Oncol Pharm Pract. 2016;22(2):205–211.

[22] Stemmler HJ, Gutschow K, Sommer H, et al. Weekly docetaxel (Taxotere®) in patients with metastatic breast cancer. Ann Oncol. 2001;12(10):1393–1398.

[23] Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol. 2005;16: iv14–iv19.

[24] Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Williston Park, NY). 2001;15(2 Supple 3):11–14.

[25] Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res. 2018;20(1):1–11.

[26] Toogood PL, Ide ND. Palbociclib (Ibrance): the first-in-class CDK4/6 inhibitor for breast cancer. Innovative Drug Synthesis. 2015:167–196.

[27] Laderian B, Fojo T. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib. December Semin Oncol. 2017;44(6):395–403. WB Saunders.

[28] Hu Q, Gong JP, Li J, et al. Down-regulation of miRNA-452 is associated with adriamycin-resistance in breast cancer cells. Asian Pac J Cancer Prev APJCP. 2014;15(13):5137–5142.

[29] Dank M. The role of aromasin in the hormonal therapy of breast cancer. Pathol Oncol Res. 2002;8:87–92.

[30] Suzuki N, Shiota T, Watanabe F, et al. Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors. Bioorg Med Chem Lett. 2011;21(6):1601–1606.

[31] Stebbing J, Copson E, O’Reilly S. Herceptin (transzumab) in advanced breast cancer. Cancer Treat Rev. 2000;26(4):287–290.

[32] Lewis JD, Chagpar AB, Shaughnessy EA, Nurko J, McMasters K, Edwards MJ. Excellent outcomes with adjuvant toremifene or tamoxifen in early-stage breast cancer. Cancer. 2010;116(10):2307–2315.

[33] Senanayake TH, Warren G, Wei X, Vinogradov SV. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates. J Contr Release. 2013;167(2):200–209.

[34] Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL, Ross JS. Topoisomerase IIα expression in breast cancer: correlation with outcome variables. Mod Pathol. 2000;13(5):542–547.

[35] Ogino M, Fujii T, Nakazawa Y, et al. Implications of Topoisomerase (TOP1 and TOP2α) expression in patients with breast cancer. In Vivo. 2020;34(6):3483–3487.

[36] Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. Breast Cancer Res Treat. 2017;166:41–54.

[37] Brueggemeier RW. Aromatase, aromatase inhibitors, and breast cancer. Am J Therapeut. 2001;8(5):333–344.

[38] Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer. 2003;3(11):821–831.

[39] Foa R, Norton L, Seidman AD. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int J Clin Lab Res. 1994;24:6–14.

[40] Peltier S, Oger JM, Lagarce F, Couet W, Benoît JP. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharmaceut Res. 2006;23:1243–1250.

[41] Alven S, Aderibigbe BA. The therapeutic efficacy of dendrimer and micelle formulations for breast cancer treatment. Pharmaceutics. 2020;12(12):1212.

[42] Zhang E, Xing R, Liu S, Li P. Current advances in development of new docetaxel formulations. Expet Opin Drug Deliv. 2019;16(3):301–312.

[43] Khan AW, Kotta S, Ansari SH, Sharma RK, Ali J. Enhanced dissolution and bioavailability of grapefruit flavonoid Naringenin by solid dispersion utilizing fourth generation carrier. Drug Dev Ind Pharm. 2015;41(5):772–779.

[44] Di H, Wu H, Gao Y, Li W, Zou D, Dong C. Doxorubicin-and cisplatin-loaded nanostructured lipid carriers for breast cancer combination chemotherapy. Drug Dev Ind Pharm. 2016;42(12):2038–2043.

[45] Zango UU, Abubakar A, Saxena R, Arya V. Phyto-nanotechnology: enhancing plant based mediated anticancer chemical therapies. Therapeutic Drug Targets and Phytomedicine for Triple Negative Breast Cancer. 2023:161.

[46] Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer Basic Clin Res. 2015;9. BCBCR-S29420.

[47] Gaba B, Khan T, Haider MF, et al. Vitamin E loaded naringenin nanoemulsion via intranasal delivery for the management of oxidative stress in a 6-OHDA Parkinson’s disease model. BioMed Res Int. 2019;2019.

[48] Bu H, He X, Zhang Z, Yin Q, Yu H, Li Y. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer. Int J Pharm. 2014;471(1–2):206–213.

[49] Alkhatib MH, Bawadud RS, Gashlan HM. Incorporation of docetaxel and thymoquinone in borage nanoemulsion potentiates their antineoplastic activity in breast cancer cells. Sci Rep. 2020;10(1):18124.

[50] Alkhatib MH, AlBishi HM. In vitro evaluation of antitumor activity of doxorubicinloaded nanoemulsion in MCF-7 human breast cancer cells. J Nanoparticle Res. 2013;15:1–15.

[51] Natesan S, Sugumaran A, Ponnusamy C, Thiagarajan V, Palanichamy R, Kandasamy R. Chitosan stabilized camptothecinnanoemulsions: development, evaluation and biodistribution in preclinical breast cancer animal mode. Int J Biol Macromol. 2017;104:1846–1852.

[52] Machado FC, de Matos RPA, Primo FL, Tedesco AC, Rahal P, Calmon MF. Effect of curcumin-nanoemulsion associated with photodynamic therapy in breast adenocarcinoma cell line. Bioorg Med Chem. 2019;27(9):1882–1890.

[53] Abedinpour N, Ghanbariasad A, Taghinezhad A, Osanloo M. Preparation of nanoemulsions of mentha piperita essential oil and investigation of their cytotoxic effect on human breast cancer lines. BioNanoScience. 2021;11:428–436.

[54] Ombredane AS, Araujo VH, Borges CO, et al. Nanoemulsion-based systems as a promising approach for enhancing the antitumoral activity of pequi oil (CaryocarbrasilenseCambess.) in breast cancer cells. J Drug Deliv Sci Technol. 2020;58:101819.

[55] Miranda SEM, de Alcântara Lemos J, Fernandes RS, et al. Enhanced antitumor efficacy of lapachol-loaded nanoemulsion in breast cancer tumor model. Biomed Pharmacother. 2021;133:110936.

[56] Haider MF, Khan S, Gaba B, et al. Optimization of rivastigmine nanoemulsion for enhanced brain delivery: in-vivo and toxicity evaluation. J Mol Liq. 2018;255:384–396.

[57] Song X, Zhang Y, Zuo R, et al. Repurposing maduramicin as a novel anticancer and anti-metastasis agent for triple-negative breast cancer as enhanced by nanoemulsion. Int J Pharm. 2022;625:122091.

[58] Wang W, Chen T, Xu H, et al. Curcumin-loaded solid lipid nanoparticles enhanced anticancer efficiency in breast cancer. Molecules. 2018;23(7):1578.

[59] Yuan Q, Han J, Cong W, et al. Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity. Int J Nanomed. 2014;9:4829, 10.18632%2Faging.103036.

[60] Baek JS, Na YG, Cho CW. Sustained cytotoxicity of wogonin on breast cancer cells by encapsulation in solid lipid nanoparticles. Nanomaterials. 2018;8(3):159.

[61] Nayek S, Raghavendra NM, Kumar BS. Development of novel S PC-3 gefitinib lipid nanoparticles for effective drug delivery in breast cancer. Tissue distribution studies and cell cytotoxicity analysis. J Drug Deliv Sci Technol. 2021;61:102073.

[62] de Sousa Marcial SP, Carneiro G, Leite EA. Lipid-based nanoparticles as drug delivery system for paclitaxel in breast cancer treatment. J Nanoparticle Res. 2017;19:1–11.

[63] Granja A, Nunes C, Sousa CT, Reis S. Folate receptor-mediated delivery of mitoxantrone-loaded solid lipid nanoparticles to breast cancer cells. Biomed Pharmacother. 2022;154:113525.

[64] Siram K, Karuppaiah A, Gautam M, Sankar V. Fabrication of hyaluronic acid surface modified solid lipid nanoparticles loaded with imatinib mesylate for targeting human breast cancer MCF-7 cells. J Cluster Sci. 2022:1–11. https://doi.org/10.1007/S10876-022-02265-y.

[65] De A, Roychowdhury P, Bhuyan NR, et al. Folic acid functionalized Diallyl Trisulfide–solid lipid nanoparticles for targeting triple negative breast cancer. Molecules. 2023;28(3):1393.

[66] Üner M, Yener G, Ergüven M. Design of colloidal drug carriers of celecoxib for use in treatment of breast cancer and leukaemia. Mater Sci Eng C. 2019;103:109874.

[67] Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Adaptation of quality by design-based development of isradipine nanostructured–lipid carrier and its evaluation for in vitro gut permeation and in vivo solubilization fate. J Pharmaceut Sci. 2018;107(11):2914–2926.

[68] Sun M, Nie S, Pan X, Zhang R, Fan Z, Wang S. Quercetin-nanostructured lipid carriers: Characteristics and anti-breast cancer activities in vitro. Colloids Surf B Biointerfaces. 2014;113:15–24.

[69] How CW, Rasedee A, Manickam S, Rosli R. Tamoxifen-loaded nanostructured lipid carrier as a drug delivery system: characterization, stability assessment and cytotoxicity. Colloids Surf B Biointerfaces. 2013;112:393–399.

[70] Ng WK, Saiful Yazan L, Yap LH, Wan Nor Hafiza WAG, How CW, Abdullah R. Thymoquinone-loaded nanostructured lipid carrier exhibited cytotoxicity towards breast cancer cell lines (MDA-MB-231 and MCF-7) and cervical cancer cell lines (HeLa and SiHa). BioMed Res Int.2015. 2015.

[71] Sabzichi M, Mohammadian J, Mohammadi M, et al. Vitamin D-loaded nanostructured lipid carrier (NLC): a new strategy for enhancing efficacy of doxorubicin in breast cancer treatment. Nutr Cancer. 2017;69(6):840–848.

[72] Singh A, Neupane YR, Panda BP, Kohli K. Lipid Based nanoformulation of lycopene improves oral delivery: formulation optimization, ex vivo assessment and its efficacy against breast cancer. J Microencapsul. 2017;34(4):416–429.

[73] Pedro IDR, Almeida OP, Martins HR, et al. Optimization and in vitro/in vivo performance of paclitaxel-loaded nanostructured lipid carriers for breast cancer treatment. J Drug Deliv Sci Technol. 2019;54:101370. https://doi.org/10.1016/j.jconrel.2022.05.034.

[74] Carvalho FVD, Ribeiro LNDM, Moura LDD, et al. Docetaxel loaded in Copaiba oilnanostructured lipid carriers as a promising DDS for breast cancer treatment. Molecules. 2022;27(24):8838.

[75] Kim CH, Kim BD, Lee TH, et al. Synergistic co-administration of docetaxel and curcumin to chemo-resistant cancer cells using PEGylated and RIPL peptideconjugated nanostructured lipid carriers. Cancer Nanotechnology. 2022;13(1):1–26.

[76] Alhalmi A, Amin S, Khan Z, et al. Nanostructured lipid carrier-based Codelivery of raloxifene and naringin: formulation, optimization, in vitro, ex vivo, in vivo assessment, and acute toxicity studies. Pharmaceutics. 2022;14(9):1771.

[77] Harada M, Iwata C, Saito H, et al. NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo. Int J Nanomed. 2012:2713–2727.

[78] Gregoriou Y, Gregoriou G, Yilmaz V, et al. Resveratrol loaded polymeric micelles for theranostic targeting of breast cancer cells. Nanotheranostics. 2021;5(1):113.

[79] Tan L, Ma B, Chen L, Peng J, Qian Z. Toxicity evaluation and anti-tumor study of docetaxel loaded mPEG-polyester micelles for breast cancer therapy. J Biomed Nanotechnol. 2017;13(4):393–408.

[80] Chu B, Shi S, Li X, et al. Preparation and evaluation of teniposide-loaded polymeric micelles for breast cancer therapy. Int J Pharm. 2016;513(1–2):118–129.

[81] Ahmad MA, Kareem O, Khushtar M, et al. Neuroinflammation: a potential risk for dementia. Int J Mol Sci. 2022;23(2):616.

[82] Chowdhury N, Chaudhry S, Hall N, et al. Targeted delivery of doxorubicin liposomes for Her-2+ breast cancer treatment. AAPS PharmSciTech. 2020;21:1–12.

[83] Ağardan NM, Değim Z, Yılmaz Ş, Altıntaş L, Topal T. Tamoxifen/raloxifene loaded liposomes for oral treatment of breast cancer. J Drug Deliv Sci Technol. 2020;57:101612.

[84] Elamir A, Ajith S, Sawaftah NA, et al. Ultrasound-triggered herceptin liposomes for breast cancer therapy. Sci Rep. 2021;11(1):1–13..

[85] Liu Z, Chen K, Davis C, et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 2008;68(16):6652–6660.

[86] Badea MA, Balas M, Prodana M, Cojocaru FG, Ionita D, Dinischiotu A. Carboxyl-functionalized carbon nanotubes loaded with cisplatin promote the inhibition of Pi3K/Akt pathway and suppress the migration of breast cancer cells. Pharmaceutics. 2022;14(2):469.

[87] Kulhari H, Pooja D, Shrivastava S, et al. Trastuzumab-grafted PAMAM dendrimers for the selective delivery of anticancer drugs to HER2-positive breast cancer. Sci Rep. 2016;6(1):23179.

[88] Torres-Pérez SA, del Pilar Ramos-Godínez M, Ramón-Gallegos E. Glycosylated onestep PAMAM dendrimers loaded with methotrexate for target therapy in breast cancer cells MDA-MB-231. J Drug Deliv Sci Technol. 2020;58:101769.

[89] Pandey P, Arya DK, Ramar MK, Chidambaram K, Rajinikanth PS. Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy. Drug Discov Today.2022.

[90] Kong T, Hao L, Wei Y, Cai X, Zhu B. Doxorubicin conjugated carbon dots as a drug delivery system for human breast cancer therapy. Cell Prolif. 2018;51(5):e12488.

[91] Zhang H, Sachdev D, Wang C, Hubel A, Gaillard-Kelly M, Yee D. Detection and downregulation of type I IGF receptor expression by antibody-conjugated quantum dots in breast cancer cells. Breast Cancer Res Treat. 2009;114:277–285.

[92] Shenoy DB, Amiji MM. Poly (ethylene oxide)-modified poly (ϵ-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm. 2005;293(1–2):261–270.

[93] Ranade AA, Joshi DA, Phadke GK, et al. Clinical and economic implications of the use of nanoparticle paclitaxel (Nanoxel) in India. Ann Oncol. 2013;24:v6–v12.

[94] Haider MD, Kanoujia J, Tripathi CB, Arya M, Kaithwas G, Saraf SA. Pioglitazone loaded vesicular carriers for anti-diabetic activity: development and optimization as per central composite design. Journal of Pharmaceutical Sciences and Pharmacology. 2015;2(1):11–20.

[95] Almoustafa HA, Alshawsh MA, Al-Suede FSR, Alshehade SA, Abdul Majid AMS, Chik Z. The chemotherapeutic efficacy of hyaluronic acid coated polymeric nanoparticles against breast cancer metastasis in Female NCr-Nu/Nu Nude mice. Polymers. 2023;15(2):284.

[96] Yıldırım M, Acet Ö, Yetkin D, Acet BÖ, Karakoç V, Odabası M. Anti-cancer activity of naringenin loaded smart polymeric nanoparticles in breast cancer. J Drug Deliv Sci Technol. 2022;74:103552.

[97] Mehrotra N, Anees M, Tiwari S, Kharbanda S, Singh H. Polylactic acid based polymeric nanoparticle mediated co-delivery of navitoclax and decitabine for cancer therapy. Nanomed Nanotechnol Biol Med. 2023;47:102627.

[98] Conte C, Longobardi G, Barbieri A, et al. Non-covalent strategies to functionalize polymeric nanoparticles with NGR peptides for targeting breast cancer. Int J Pharm. 2023:122618.

[99] Prasad bn, padmesh tvn, suganya k, govindaraju k, kumar vg, anand kv. Structural and optical properties of water-soluble iron nanoparticles using mimosa pudica leaf extract via green route. University politehnica of bucharest scientific bulletin series bchemistry and materials science. 2016;78(2):177–184.

[100] Al-Radadi NS. Green biosynthesis of flaxseed gold nanoparticles (Au-NPs) as potent anti-cancer agent against breast cancer cells. J Saudi Chem Soc. 2021;25(6):101243.

[101] Khodashenas B, Ardjmand M, Rad AS, Esfahani MR. Gelatin-coated gold nanoparticles as an effective pH-sensitive methotrexate drug delivery system for breast cancer treatment. Mater Today Chem. 2021;20:100474.

[102] Chaudhari R, Nasra S, Meghani N, Kumar A. MiR-206 conjugated gold nanoparticle based targeted therapy in breast cancer cells. Sci Rep. 2022;12(1):4713.

[103] Kang KW, Chun MK, Kim O, et al. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomed Nanotechnol Biol Med. 2010;6(2):210–213.

[104] Kelidari HR, Alipanah H, Roozitalab G, Ebrahimi M, Osanloo M. Anticancer effect of solid-lipid nanoparticles containing Mentha longifolia and Mentha pulegium essential oils: in vitro study on human melanoma and breast cancer cell lines. Biointerface Research in Applied Chemistry. 2022;12(2):2128–2137.

[105] Goyal P, Goyal K, Kumar SV, Singh AOMPK, Katare OP, Mishra DN. Liposomal drug delivery systems–clinical applications. Acta Pharm. 2005;55(1):1–25.

[106] Wong MY, Chiu GN. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen-receptor-negative breast cancer treatment. Anti Cancer Drugs. 2010;21(4):401–410.

[107] Khan Zoya, Faheem Haider Md, Nazish Naseem, Aftab Siddiqui Mohd, Usama Ahmad, Muazzam Khan Mohd. Nanocarrier for the treatment of liver cancer. J Pharmaceut Sci Res. 2022;14(11):944–957.

[108] Adnan M, Akhter MH, Afzal O, et al. Exploring nanocarriers as treatment modalities for Skin cancer. Molecules. 2023;28(15):5905.

[109] Soe ZC, Kwon JB, Thapa RK, et al. Transferrin-conjugated polymeric nanoparticle for receptor-mediated delivery of doxorubicin in doxorubicin-resistant breast cancer cells. Pharmaceutics. 2019;11(2):63.

[110] Adnan M, Haider MF, Naseem N, Haider T. Transethosomes: a promising challenge for topical delivery Short Title: Transethosomes for topical delivery. Drug Research. 2023;73(4):200–212.

[111] Kamel AE, Fadel M, Louis D. Curcumin-loaded nanostructured lipid carriers prepared using Peceol™ and olive oil in photodynamic therapy: development and application in breast cancer cell line. Int J Nanomed;2019:5073–5085. https://www.dovepress.com/by146.185.203.38. Accessed July 14, 2019.

[112] Srivastava S, Haider MF, Ahmad A, Ahmad U, Arif M, Ali A. Exploring nanoemulsions for prostate cancer therapy. Drug Research. 2021;71(8):417–428.

[113] Uppal S, Sharma P, Kumar R, Kaur K, Bhatia A, Mehta SK. Effect of benzyl isothiocyanate encapsulated biocompatible nanoemulsion prepared via ultrasonication on microbial strains and breast cancer cell line MDA MB 231. Colloids Surf A Physicochem Eng Asp. 2020;596:124732.

RIGHTS & PERMISSIONS

2024 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.